Dr. Kiem is the Sponsor of multiple clinical trials investigating how gene therapy can be used to improve the treatment of infectious diseases, genetic diseases, and malignancies. Dr. Kiem's four Investigational New Drugs (INDs) currently cover trials for HIV, Fanconi Anemia, and glioblastoma.
If you are a patient seeking more information about a clinical trial, please use the links below to learn about the trials to see if you may qualify to participate.
Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients with HIV-Associated Lymphoma (ClinicalTrials.gov Identifier NCT02378922)
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients with Lymphoma With HIV Infection (ClinicalTrials.gov Identifier NCT02343666)
Gene Therapy for Fanconi Anemia (ClinicalTrials.gov Identifier NCT01331018)
Dose-Intensive Chemotherapy in Combination with Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas (ClinicalTrials.gov Identifier NCT00669669)
Every year, hundreds of patients enroll in clinical trials developed by doctors at Fred Hutch. The Seattle Cancer Care Alliance is Fred Hutch's clinical care partner and is able to provide world-class cancer treatment for patients as well as the infrastructure to support cutting edge therapies provided to trial enrollees.
To learn more ongoing clinical trials, as well as an overview of potential risks and benefits, please see the Clinical trial pages for Fred Hutch and Seattle Cancer Care Alliance